March 22, 2024
As previously announced, the agenda includes:
- Proposals to re-appoint Chairman
Feike Sijbesma (Dutch, 1959) andPeter Löscher (Austrian, 1957) as members of the Supervisory Board, with effect fromMay 7, 2024 . - Proposal to appoint
Charlotte Hanneman (Dutch, 1978) as member of theBoard of Management , fulfilling the role of Chief Financial Officer, with effect fromOctober 1, 2024 . - Proposal to appoint
Benoît Ribadeau-Dumas (French, 1972) as new member of the Supervisory Board, with effect fromMay 7, 2024 .
The agenda furthermore includes:
- Proposals to adopt an amended Remuneration Policy for the
Board of Management and an amended Remuneration Policy for the Supervisory Board. - A number of recurring items, such as the 2023 Remuneration Report as included in the Annual Report 2023 (advisory vote), and the proposals to adopt the company’s financial statements and dividend.
The AGM will be held at the
The complete agenda with explanatory notes, the Annual Report 2023 (which was published on
For further information, please contact:
Philips External Relations
Tel.: +31 6 8103 9584
E-mail: elco.van.groningen@philips.com
Dorin Danu
Philips Investor Relations
Tel: +31 20 5977055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in
Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
© OMX, source